SCHEMBL5519985

SCHEMBL5519985

CC(C)(C)OC(=O)N1CCC(C(=O)NCC(SCc2ccccn2)C(=O)NCC#N)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.44
GPR119 Q8TDV5 3/20 0.44
KDM4E B2RXH2 2/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 1/20 0.42
THRB P10828 1/20 0.42
POLB P06746 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
USP30 Q70CQ3 1/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6874032 0.90 KMT2A (0.43) KDM4EPKMLMNAPOLBCYP2D6
SCHEMBL5532239 0.76 CTSS (0.46) STSGPR119KDM4EPKMTHRB
SCHEMBL17048460 0.76 GAA (0.59) PKMLMNATHRBMEN1GAA
SCHEMBL17104852 0.76 GAA (0.59) PKMLMNATHRBMEN1GAA
SCHEMBL29566603 0.72 GPR119 (0.61) GPR119KDM4EPKMLMNATHRB
SCHEMBL1088570 0.72 GPR119 (0.61) GPR119KDM4EPKMLMNATHRB
SCHEMBL30879857 0.71 TSHR (0.57) PKMLMNATHRBMEN1GAA
SCHEMBL30879900 0.71 TSHR (0.57) PKMLMNATHRBMEN1GAA
SCHEMBL28463063 0.70 PTPN2 (0.62) STSGPR119LMNAPTPN2PTPN1
SCHEMBL12804554 0.69 NPSR1 (0.68) STSGPR119KDM4EPKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-20030096796-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-05-22 US disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096796-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 STS 843/4885GPR119 4611/4885KDM4E 2428/4885
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 STS 843/4885GPR119 4611/4885KDM4E 2428/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 STS 843/4885GPR119 4611/4885KDM4E 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.